Perspective Therapeutics (CATX) Insider Trading & Ownership $2.42 +0.09 (+3.65%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock Perspective Therapeutics (NYSE:CATX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.52%Number OfInsiders Buying(Last 12 Months)6Amount OfInsider Buying(Last 12 Months)$898,619.00Number OfInsiders Selling(Last 12 Months)0 Get CATX Insider Trade Alerts Want to know when executives and insiders are buying or selling Perspective Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CATX Insider Buying and Selling by Quarter Perspective Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/31/2025Robert F Williamson IIIDirectorBuy38,145$2.14$81,630.30 3/28/2025Johan M SpoorCEOBuy22,026$2.24$49,338.24 3/28/2025Juan GrahamCFOBuy33,333$2.25$74,999.25 3/28/2025Robert F Williamson IIIDirectorBuy22,192$2.27$50,375.84 12/4/2024Heidi HensonDirectorBuy25,975$3.85$100,003.75 12/4/2024Johan M SpoorCEOBuy8,000$3.77$30,160.00 11/25/2024Johan M SpoorCEOBuy14,500$3.78$54,810.00 11/25/2024Jonathan Robert HuntCFOBuy12,829$3.82$49,006.78 11/25/2024Robert F Williamson IIIDirectorBuy6,266$3.64$22,808.24 6/17/2024Jonathan Robert HuntCFOBuy1,800$9.81$17,658.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/14/2024Lori A WoodsDirectorBuy4,587$10.90$49,998.30 6/13/2024Johan M SpoorCEOBuy10,000$11.70$117,000.00 6/3/2024Lori A WoodsDirectorBuy3,424$14.60$49,990.40 5/31/2024Jonathan Robert HuntCFOBuy2,500$14.00$35,000.00 5/31/2024Robert F Williamson IIIDirectorBuy5,500$13.80$75,900.00 5/29/2024Robert F Williamson IIIDirectorBuy3,003$13.30$39,939.90 (Data available from 1/1/2013 forward) CATX Insider Trading Activity - Frequently Asked Questions Who is on Perspective Therapeutics's Insider Roster? The list of insiders at Perspective Therapeutics includes Heidi Henson, Johan M Spoor, Jonathan Robert Hunt, Juan Graham, Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, and Robert F Williamson III. Learn more on insiders at CATX. What percentage of Perspective Therapeutics stock is owned by insiders? 3.52% of Perspective Therapeutics stock is owned by insiders. Learn more on CATX's insider holdings. Which Perspective Therapeutics insiders have been buying company stock? The following insiders have purchased CATX shares in the last 24 months: Heidi Henson ($100,003.75), Johan M Spoor ($251,308.24), Jonathan Robert Hunt ($134,164.78), Juan Graham ($74,999.25), Lantheus Alpha Therapy, Llc ($57,409,478.50), Lori A Woods ($99,988.70), Markus Puhlmann ($192,156.60), and Robert F Williamson III ($301,472.18). How much insider buying is happening at Perspective Therapeutics? Insiders have purchased a total of 6,323,329 CATX shares in the last 24 months for a total of $58,563,572.00 bought. Perspective Therapeutics Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Compensation: $855.78k3 recent tradesMr. Jonathan R. Hunt (Age 57)CFO and Principal Financial & Accounting Officer Compensation: $944.35k1 recent tradesDr. Markus Puhlmann M.B.A. (Age 58)M.D., Chief Medical Officer Compensation: $633.14kMr. Shane CobbExecutive Vice President of OperationsDr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsSteve KeefeSenior Vice President of Clinical Development More Insider Trading Tools from MarketBeat Related Companies RXST Insider Selling AVNS Insider Selling SIBN Insider Selling KIDS Insider Selling BBNX Insider Selling TMCI Insider Selling DCTH Insider Selling NPCE Insider Selling SMLR Insider Selling CLPT Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market Sentiment This page (NYSE:CATX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CATX Stock Free CATX Stock Alerts